NHRI researchers report resident vs. non-resident human multipotent mesenchymal stromal/stem cell (MSC) interactions with B lymphocytes result in disparate outcomes

Multipotent human mesenchymal stromal/stem cells (MSCs) from multiple organs including the bone marrow (BM) and placenta (P‐MSCs) harbor clinically relevant immunomodulation best demonstrated toward T lymphocytes. Surprisingly, little in known on its interactions with B lymphocytes, which originate from the BM where there is a resident MSC. Dr. B. Linju…

Continue reading

NHRI researcher reports lipocalin‐2 mediates the rejection of neural transplants

Cell replacement therapy has been investigated as a potential treatment for neurological disorders including stroke, Parkinson’s disease, and traumatic brain injury. Intracerebral transplantation may, however, trigger an immune response that results in rejection of the engrafted neurons. Thus, understanding the immune mechanisms of graft rejection is essential to improve cell…

Continue reading

NHRI researcher reports early sexual initiation and risky sexual practices are mediated through preceding-sex use of illicit drugs

The Global Burden of Disease Study 2016 has ranked unsafe sex as the 13th risk factors. Early sexual initiation (< 16 years) has been associated with various risky sexual practices, such as multiple sexual partners, sex with non regular partners, sex under the influence of alcohol or drugs, and condom…

Continue reading

NHRI researcher reports nanoemulsion adjuvantation strategy of tumor-associated antigen therapy rephrases mucosal and immunotherapeutic signatures following intranasal vaccination

Mucous membranes serve as the primary barrier against pathogen at respiratory, digestive and reproductive tracts. However, mucosal administration of vaccines induce minuscule immune responses due to mucosal membrane barriers and immune tolerances. Therefore, a safe mucosal adjuvant with high efficacy is necessary for antigen recognition by the mucosal immune system…

Continue reading

NHRI researcher reports activation of M1 macrophages in response to recombinant TB vaccines with enhanced anti-mycobacterial activity

Pulmonary tuberculosis (TB) is a difficult to eradicate infectious disease. Although the Bacille Calmette–Guérin (BCG) vaccine against Mycobacterium tuberculosis (MTB) has been available for decades, its efficacy is variable and has lessened over time. Furthermore, studies have shown that BCG vaccine no longer protects against newly emerged Beijing strains which…

Continue reading

A Novel Chemotherapy Regimen (SLOG) in Metastatic Pancreatic Cancer with Promising Efficacies
─NHRI has established a novel chemotherapy regimen, SLOG, with promising activity and safety profiles in the treatment of metastatic pancreatic cancer ─

November 30, 2020 Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal malignant disease. Nearly 80–85% of patients presented with locally advanced or metastatic diseases at the time of diagnosis, and the overall 5-year survival rate is about 8% globally. Systemic chemotherapy is the standard of care for patients with unresectable…

Continue reading

A Safer Opioid Painkiller with Low Side-Effects
─NHRI has discovered a series of opioid receptor/nociception receptor dual agonists with fast and potent antinociception, fewer side-effects than morphine ─

November 23, 2020 The Ministry of Science and Technology has presented its 2020 Future Tech Breakthrough Award (Heterocyclic compounds and use thereof) to the National Health Research Institutes (NHRI) for the discovery of painkilling compounds that are safer and have fewer side effects than morphine. The work was performed by…

Continue reading

NHRI researcher examines the association between oral corticosteroid bursts and severe adverse events

Dr. Hui-Ju Tsai from the Institute of Population Health Sciences and collaborators examined the associations between steroid bursts and severe adverse events, specifically gastrointestinal (GI) bleeding, sepsis, and heart failure. The research findings have been published in Annals of Internal Medicine. This video provides additional insight of the study. Citation:…

Continue reading

NHRI reviews current status of mesenchymal stem cell therapy for immune/inflammatory lung disorders and gleans insights for possible use in COVID‐19

The broad immunomodulatory properties of human mesenchymal stem cells (MSCs) has allowed for wide application in regenerative medicine as well as immune/inflammatory diseases including severe pulmonary injury and inflammation such as acute respiratory distress syndrome (ARDS) associated with bacterial and viral infections. In light of the novel COVID-19 pandemic, MSC…

Continue reading